- Ring The Bell
- Posts
- 🤏 Why Small Thinking Could Lead To Big Results
🤏 Why Small Thinking Could Lead To Big Results
Plus, the lesser-known health care stocks to jettison, and more
You're receiving this email because you're subscribed to Ring the Bell from Benzinga. To manage your subscription, click the link at the bottom of this email.
It’s Friday! Small-cap stocks are showing signs of strength as the Russell 2000 eyes a breakout, potentially outpacing the S&P 500 if cyclical trends gain momentum. Here’s what investors should watch — and how to position for a potential shift in market leadership. Also, read about health care minnows you should probably exit from.
—Josh Enomoto
Plus, if you’re interested in advanced biopharmaceutical solutions, check out today’s sponsor.
MARKET RECAP
Yesterday: Stocks declined Thursday as weaker-than-expected guidance from Walmart weighed on sentiment, with financials and consumer discretionary sectors leading losses. Bond yields dipped, while oil prices climbed following supply disruptions linked to geopolitical tensions. Investors are now watching labor market trends and economic indicators for clues on future Fed policy shifts.
On Our Radar: After reviewing existing home sales, analysts will next turn to Tuesday’s consumer confidence report. On the earnings front, Diamondback Energy and EV maker Li Auto will disclose their financial results.
TOP STORY
The S&P 500 remains in bullish territory, but small caps are quietly gaining traction, hinting at a potential shift in market leadership.
SPONSORED CONTENT
The human body’s circulatory system comprises blood vessels that carry blood. Arteries carry blood away from the heart, veins carry blood back and capillaries are tiny blood vessels that connect arteries and veins.
Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases and areas of unmet medical need, is utilizing its pharmaceutical expertise to treat Behçet’s disease, an autoimmune condition mainly associated with inflammation of the blood vessels and the eyes, though it often causes many different issues throughout the body.
In 2024, Soligenix announced the phase 2 clinical trial of its candidate SGX945 for the treatment of the oral, genital and potentially skin ulcers associated with Behçet’s disease.
This is a paid ad. Please see 17b disclosure here for more information.
FIVE ZINGERS
Tax Time: While cryptos have represented a powerful asset class, they suffer from complex tax structures. These are the mistakes you must avoid this year.
Gold Rush: Rising concerns over geopolitical instability have sparked a massive influx in gold ETFs. Read more about the core catalysts fueling the rally.
Tariff Blues: Big-box retailer Walmart suffered a sizable decline after issuing fiscal 2026 guidance that fell below expectations. Learn why economic policies are hurting the discount giant.
High Seas: Cruise ship stocks suffered badly on Thursday following the possibility of U.S. tax imposition. Still, read why some analysts believe the volatility is an overreaction.
Cut Down: A federal judge turned down an appeal by multiple government employee unions seeking to halt President Trump's downsizing initiative. Here's how the matter may play out next.
ONE FOR THE ROAD
As of Feb. 20, 2025, three stocks in the healthcare sector could be flashing a real warning to investors who value momentum as a key criterion in their trading decisions.
The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
SPECIAL OFFER
Markets are moving fast—do you have a strategy? Join Matt Maley on Sunday, February 23, at 1 PM ET for a live, interactive strategy session on trading this week’s biggest opportunities. Learn how to profit from earnings reactions, technical breakouts and macro-driven swings. Save your seat today!
BEFORE YOU GO
Were you forwarded this email? Click here to subscribe.
And be sure to check out our other newsletters:
Future Finance: Where fintech, crypto and the future of finance collide. Future Finance is a perfect lunch read packed with quick bites for industry enthusiasts. Subscribe here.
Cannabis Daily: A must-read daily briefing for cannabis investors, operators and enthusiasts. Join our list of industry veterans to jump start your morning. Subscribe here.
Real Estate Weekly: Ready to elevate your real estate game? This weekly newsletter provides actionable insights whether you are investing in REITs, owning property or delving into the fast-growing world of fractional real estate. Subscribe here.
Advisor: Tailor-made for Financial Advisors, this weekly newsletter has industry-specific insights, analysis and news. Subscribe here.
Tech Trends: Get the inside scoop on AI, the hottest gadgets and mind-blowing tech trends. Subscribe here.